Home/Filings/4/0000950170-23-070886
4//SEC Filing

HIMES VAUGHN B 4

Accession 0000950170-23-070886

CIK 0001060736other

Filed

Dec 14, 7:00 PM ET

Accepted

Dec 15, 6:55 PM ET

Size

72.1 KB

Accession

0000950170-23-070886

Insider Transaction Report

Form 4
Period: 2023-12-14
HIMES VAUGHN B
EVP, Technical Operations
Transactions
  • Disposition to Issuer

    Common Stock

    2023-12-14$229.00/sh14,874$3,406,1460 total
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1434,9460 total
    Exercise: $39.15Exp: 2025-08-25Common stock (34,946 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1447,8440 total
    Exercise: $46.37Exp: 2027-08-17Common stock (47,844 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-141,3010 total
    Exercise: $76.86Exp: 2028-08-30Common stock (1,301 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-146360 total
    Exercise: $161.82Exp: 2030-08-17Common stock (636 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1420,6260 total
    Exercise: $155.87Exp: 2031-08-16Common stock (20,626 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-1411,4690 total
    Common stock (11,469 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-143,2040 total
    Common stock (3,204 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-145,0910 total
    Common stock (5,091 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,8270 total
    Common stock (1,827 underlying)
  • Disposition to Issuer

    Common Stock

    2023-12-14$229.00/sh119,471$27,358,8590 total(indirect: By Trust)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1440,2930 total
    Exercise: $45.30Exp: 2026-08-27Common stock (40,293 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1441,3430 total
    Exercise: $76.86Exp: 2028-08-30Common stock (41,343 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1441,4530 total
    Exercise: $72.64Exp: 2029-08-30Common stock (41,453 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-141,3330 total
    Exercise: $72.64Exp: 2029-08-30Common stock (1,333 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1415,7190 total
    Exercise: $161.82Exp: 2030-08-17Common stock (15,719 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-148,3330 total
    Exercise: $34.20Exp: 2026-05-09Common stock (8,333 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-144,3580 total
    Common stock (4,358 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,2750 total
    Common stock (1,275 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-147650 total
    Common stock (765 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-142,5480 total
    Common stock (2,548 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,5290 total
    Common stock (1,529 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1417,6620 total
    Exercise: $44.09Exp: 2024-08-26Common stock (17,662 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-12-146420 total
    Exercise: $155.87Exp: 2031-08-16Common stock (642 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-141,6490 total
    Common stock (1,649 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-149,0100 total
    Common stock (9,010 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-141,2140 total
    Common stock (1,214 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-142,8000 total
    Common stock (2,800 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-145100 total
    Common stock (510 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-149,7450 total
    Common stock (9,745 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-1411,0850 total
    Common stock (11,085 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,0190 total
    Common stock (1,019 underlying)
Footnotes (8)
  • [F1]Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
  • [F2]Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
  • [F3]Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
  • [F4]Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
  • [F5]Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
  • [F6]Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
  • [F7]Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
  • [F8]Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.

Documents

1 file

Issuer

Seagen Inc.

CIK 0001060736

Entity typeother

Related Parties

1
  • filerCIK 0001361966

Filing Metadata

Form type
4
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 6:55 PM ET
Size
72.1 KB